Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + SBRT + Chemotherapy in Locally Advanced Pancreatic Cancer
NCT06844422Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pancreatic cancer (PC), sponsored by Shandong Cancer Hospital. Primary endpoints: Maximum Tolerated Dose at 1 year, Dose-Limiting Toxicity at 1 year and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06844422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844422.